36. 表皮水疱症 Epidermolysis bullosa Clinical trials / Disease details

臨床試験数 : 163 /  薬物数 : 185 - (DrugBank : 46) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 125

  
3 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05651607
(ClinicalTrials.gov)		January 20237/12/2022Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis BullosaEvaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis BullosaHereditary Epidermolysis BullosaDrug: CannabidiolAssistance Publique - Hôpitaux de ParisHELEBOR;Fondation Apicil;Lions Club International FoundationNot yet recruiting2 Years17 YearsAll10Phase 2France
2NCT04613102
(ClinicalTrials.gov)		August 1, 202027/10/2020The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III TrialThe Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III TrialEpidermolysis Bullosa;Pain;ItchDrug: AVCN583601 (3% Cannabidiol cream)Elena PopeAvicanna IncWithdrawn4 Years50 YearsAll0Phase 2/Phase 3Canada
3EUCTR2021-000103-20-NL
(EUCTR)		15/07/2021A study on the effect of Transvamix on pain in adults with epidermolysis bullosa.An explorative randomized, placebo-controlled and double-blind intervention crossover study: Transvamix (100mg/mL THC / 50mg/mL CBD) to treat chronic pain in Epidermolysis Bullosa Genetic Epidermolysis Bullosa;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]Product Name: Transvamix (100mg/mL THC, 50mg/mL CBD)
INN or Proposed INN: THC
Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL
INN or Proposed INN: CBD
Other descriptive name: CANNABIDIOL		University Medical Center GroningenNULLNAFemale: yes
Male: yes		16Phase 2Netherlands